ADVERTISEMENT Fed. Circ. Judge Unsure IP At Heart Of $1.1B Juno Win Is Valid Law360 (July 6, 2021, 8:46 PM EDT) -- The Federal Circuit's chief judge appeared receptive Tuesday to Kite Pharma's argument that a Juno Therapeutics drug patent is too broad to be valid, potentially calling into question Juno's more than $1.1 billion infringement win during the appellate court's first in-person hearing since the arrival of the COVID-19 pandemic. The three-judge panel was considering Kite Pharma Inc.'s appeal of a California federal judge's final judgment, which tacked $389 million in enhanced damages onto a $752 million jury verdict that found Kite willfully infringed Juno's patent with its own immunotherapy cancer drug, Yescarta.